Does maintenance therapy have a role in mantle cell lymphoma treatment?

References

• Vose J. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017;92:806–813.
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomised trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984–1992.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicenter, randomised, phase 3 non-inferiority trial. Lancet Oncol. 2013;381:1203–1210.
   Google Scholar
• Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. NEJM. 2015;372:944–953.
   PubMed Web of Science ®Google Scholar
• Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. JCO. 2013;31(11):1442–1449.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Annals of Oncol. 2017;28(4):iv62–iv71.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. Guidelines for non-Hodgkin’s lymphoma version 3.2017 [cited 2018 Feb 4]. Available from: http://www.nccn.org
   Google Scholar
• Arranz R, Garcia-Alfonso P, Sobrino P, et al. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade NHL: results from a prospective, multicenter trial with double randomisation. J Clin Oncol. 1998;16:1538–1546.
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Carde P, Meerwaldt JH, et al. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-hodgkin’s lymphoma. J Clin Oncol. 1998;16:41–47.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Dana BW, LeBlanc M, et al. Interferon alfa consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-hodgkin’s lymphoma: results of the Southwest oncology group randomised phase III study 8809. J Clin Oncol. 2000;18:2010–2016.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. NEJM. 2012;367:520–531.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Knauf W, Goerner M, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2016;34(suppl; abstr 7503).
   Google Scholar
• Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. NEJM. 2017;377:1250–1260.
   PubMed Web of Science ®Google Scholar
• Hoster E, Kluin-Nelemans HC, Hermine O, et al. Rituximab maintenance after first-line immunochemotherapy in mantle cell lymphoma: long-term follow-up of the randomized European MCL elderly trial. Presented at the 59th Annual Meeting of the American Society of Hematology; 2017 Dec 9–12; Atlanta, GA.
   Google Scholar
• Vidal L, Gafter-Gvili A, Dreyling M, et al. Maintenance therapy for patients with Mantle Cell Lymphoma (MCL) – a systematic review and meta-analysis of Randomized Controlled Trials (RCTs). Poster session presented at: 58th Annual Meeting of the American Society of Hematology; 2016 Dec 3–6; San Diego, CA.
   Google Scholar
• Kolstad A, Pedersen LB, Eskelund CW, et al. Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years. Biol Blood Marrow Transplan. 2017;23:428–453.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz S-F, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Cancer Research (SAKK). J Clin Oncol. 2005;23:705–711.
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomised study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108(13):4003–4008.
   PubMed Web of Science ®Google Scholar
• Rummel M, Kaiser U, Balser M, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17:57–66.
   PubMed Web of Science ®Google Scholar
• Trneny M, Lamy T, Walewski J, et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicenter trial. Lancet Oncol. 2016;17:319–331.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. NEJM. 2015;373:1835–1844.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Cristos PJ, et al. Initial treatment with lenalidomide plus rituximab for mantle cell lymphoma: 5-year follow-up and correlative analysis from a multi-center phase II study. Presented at the 59th Annual Meeting of the American Society of Hematology; 2017 Dec 9–12;Atlanta, GA.
   Google Scholar
• Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haem. 2012;159:154–163.
   PubMed Web of Science ®Google Scholar
• Zaja F, Ferrero S, Stelitano C, et al. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. Haematologica. 2017;102:e203.
   PubMed Web of Science ®Google Scholar
• Doorduijn JK, Minnema MC, Kersten MJ, et al. Bortezomib maintenance therapy after induction with R-CHOP, ara-C and autologous stem cell transplantation in newly diagnosed MCL patients, results of a multicentre phase II HOVON study. Blood. 2015;126:339.
   Web of Science ®Google Scholar
• Kaplan LD, Jung S-H, Stock W, et al. Bortezomib Maintenance (BM) versus Consolidation (BC) following aggressive immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for untreated Mantle Cell Lymphoma (MCL): CALGB (alliance) 50403. Blood. 2015;126:337.
   Web of Science ®Google Scholar
• Till BG, Li H, Bernstein SH, et al. Phase II triaL of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haem. 2016;172(2):208–218.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Hoellein A, Decker T, et al. Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study. Leukaemia and Lymphoma. 2015;56(11):3227–3229.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. NEJM. 2013;369(6):507–516.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet Oncol. 2014;387:770–778.
   Google Scholar
• Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17:48–56.
   PubMed Web of Science ®Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Efficacy and safety of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma in the phase 2 ACE-LY-004 study. Presented at the 59th Annual Meeting of the American Society of Hematology; 2017 Dec 9–12; Atlanta, GA.
   Google Scholar
• Jerkeman M, Hutchings M, Raty R, et al. Ibrutinib-lenalidomide-rituximab in patients with relapsed/refractory mantle cell lymphoma: first results from the nordic lymphoma group MCL6 (PHILEMON) phase II trial. Paper presented at: 58th Annual Meeting of the American Society of Hematology; 2016 Dec 3–6;San Diego, CA.
   Google Scholar